According to bluebird bio 's latest financial reports the company's current earnings (TTM) are -$91.14 M. In 2022 the company made an earning of -$0.27 B an increase over its 2021 earnings that were of -$0.33 B.The earnings displayed on this page are the earnings before interest and taxes or simply EBIT.
Year | Earnings | Change |
---|---|---|
2023 (TTM) | -$91.14 M | -65.8% |
2022 | -$0.27 B | -18.85% |
2021 | -$0.33 B | -46.87% |
2020 | -$0.62 B | -21.79% |
2019 | -$0.8 B | 42.26% |
2018 | -$0.56 B | 65.59% |
2017 | -$0.34 B | 27% |
2016 | -$0.27 B | 58.42% |
2015 | -$0.17 B | 175.54% |
2014 | -$60.51 M | 138.96% |
2013 | -$25.33 M | 6.98% |
2012 | -$23.67 M |
Company | Earnings | Earnings differencediff. | Country |
---|---|---|---|
Sanofi SNY | $7.26 B | -8,066.91% | ๐ซ๐ท France |
Merck MRK | $3.03 B | -3,430.15% | ๐บ๐ธ USA |
Sangamo Therapeutics
SGMO | -$0.12 B | 30.56% | ๐บ๐ธ USA |
Acceleron Pharma XLRN | -$0.26 B | 180.34% | ๐บ๐ธ USA |
GlycoMimetics
GLYC | -$36.9 M | -59.51% | ๐บ๐ธ USA |
BioMarin Pharmaceutical BMRN | $0.23 B | -360.44% | ๐บ๐ธ USA |